| Collaboration |
Abstral |
| Geography |
China |
| Type of agreement |
License and distribution agreement |
| Signed |
January 2009 |
| Potential milestones |
USD 4.75m |
Abstral
Through a licensing and distribution agreement, the Chinese pharmaceutical company NovaMed has exclusive rights to market and sell Abstral™ in China. NovaMed is handling the registration application for Abstral™ in this market. According to the agreement, the potential milestone payments and initial payment total USD 4.75m.
About NovaMed Pharmaceuticals
NovaMed Pharmaceuticals was founded in August 2005 to provide a one-stop-shop service for global pharmaceutical companies and brand owners looking to leverage cost advantage and achieve optimal market potential in China. Through a directly managed sales organization of 400 people, an exclusive network of best-in-class research, development, regulatory and distribution partners, NovaMed has built viable commercialization models for products at different stages of their lifecycle. These include products already commercially available in China, internationally approved products not yet registered in China, and in-license late stage development compounds.